Serbin M, Mansfield C, Leach CA, Yonan C, Klepitskaya O, Sheehan M, Donnelly A. Do patients' experiences with side effects affect their preferences for adjunctive Parkinson's disease treatments? Poster presented at the 8th European Academy of Neurology Congress; June 25, 2022. Vienna, Austria. [abstract] Eur J Neurol. 2022 Jun; 29(Suppl 1):446.
Peay HL, Fischer R, Mange B, Paquin RS, Smith EC, Sadosky A, Russo L, Ricotti V, Rensch C, Morris C, Martin AS, Ganot A, Beaverson K, Mansfield C. Patients' and caregivers' maximum acceptable risk of death for non-curative gene therapy to treat Duchenne muscular dystrophy. Mol Genet Genomic Med. 2021 May;9(5):e1664. doi: 10.1002/mgg3.1664
Novick D, Reed C, Haro JM, Gonzalez-Pinto A, Perrin E, Aguado J, Tohen M. Comparison of olanzapine and risperidone in the EMBLEM study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010 Sep;25(5):257-63.
Lee E, Candrilli SD, Roberts CS, Tang SSK, Bassin S, Wong ND. Regional Differences in the Prevalence, Treatment and Control of Hypertension and Dyslipidemia in Us Urban Hispanic Populations Participating in Health Screening Events. Ethn Dis. 2008 Sep 1;18(4):409-14.
Quandt SA, Graham CN, Bell RA, Snively BM, Golden SL, Stafford JM, Arcury TA. Ethnic disparities in health-related quality of life among older rural adults with diabetes. Ethn Dis. 2007;17(3):471-6.